Loading...
•
Dec 31, 2024
Zimmer Biomet Q4 2024 Earnings Report
Zimmer Biomet reported fourth quarter and full-year results, exceeding financial guidance and making strategic moves towards portfolio diversification.
Key Takeaways
Zimmer Biomet announced Q4 2024 net sales of $2.023 billion, a 4.3% increase, with diluted earnings per share at $1.20 and adjusted diluted earnings per share at $2.31. Full-year net sales reached $7.679 billion, up 3.8%, with diluted earnings per share at $4.43 and adjusted diluted earnings per share at $8.00. The company also provided full-year 2025 financial guidance and announced an agreement to acquire Paragon 28.
Fourth quarter net sales increased by 4.3% to $2.023 billion, or 4.9% on a constant currency basis.
Diluted earnings per share for the fourth quarter were $1.20, with adjusted diluted earnings per share at $2.31.
Full-year net sales reached $7.679 billion, representing a 3.8% increase, or 4.8% on a constant currency basis.
Full-year diluted earnings per share were $4.43, and adjusted diluted earnings per share were $8.00.
Revenue by Segment
Forward Guidance
The Company is providing the following full-year 2025 financial guidance: Projected Year Ending December 31, 2025 2025 Reported Revenue Change 1.0% - 3.5% Foreign Currency Exchange Impact (2.0)% - (1.5)% 2025 Constant Currency Revenue Change 3.0% - 5.0% Adjusted Diluted EPS(1) $8.15 - $8.35
Positive Outlook
- Projected Year Ending December 31, 2025
- 2025 Reported Revenue Change 1.0% - 3.5%
- Foreign Currency Exchange Impact (2.0)% - (1.5)%
- 2025 Constant Currency Revenue Change 3.0% - 5.0%
- Adjusted Diluted EPS(1) $8.15 - $8.35
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...